131 related articles for article (PubMed ID: 28854670)
1. Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections.
Feng Y; Bakker RT; van Hest RM; Hodiamont CJ; Brul S; Schultsz C; Ter Kuile BH
FEMS Microbiol Lett; 2017 Aug; 364(14):. PubMed ID: 28854670
[TBL] [Abstract][Full Text] [Related]
2. Development of Antibiotic Resistance during Simulated Treatment of Pseudomonas aeruginosa in Chemostats.
Feng Y; Hodiamont CJ; van Hest RM; Brul S; Schultsz C; Ter Kuile BH
PLoS One; 2016; 11(2):e0149310. PubMed ID: 26872140
[TBL] [Abstract][Full Text] [Related]
3. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
Henrichfreise B; Wiegand I; Luhmer-Becker I; Wiedemann B
Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
[TBL] [Abstract][Full Text] [Related]
4.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
5. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
6. Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime.
Bowler LL; Zhanel GG; Ball TB; Saward LL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4976-9. PubMed ID: 22777043
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains.
Drenjancević D; Vranes J; Bedenić B; Sakić-Zdravcević K
Coll Antropol; 2007 Mar; 31(1):221-5. PubMed ID: 17598405
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
[TBL] [Abstract][Full Text] [Related]
10. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN
J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
12. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
13. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
[TBL] [Abstract][Full Text] [Related]
14. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Oie S; Sawa A; Kamiya A; Mizuno H
J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987
[TBL] [Abstract][Full Text] [Related]
15. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biofilm formation and antibiotic resistance pattern of Pseudomonas aeruginosa in human and environmental isolates.
Gholami S; Tabatabaei M; Sohrabi N
Microb Pathog; 2017 Aug; 109():94-98. PubMed ID: 28549926
[TBL] [Abstract][Full Text] [Related]
17. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.
Bonfiglio G; Carciotto V; Russo G; Stefani S; Schito GC; Debbia E; Nicoletti G
J Antimicrob Chemother; 1998 Feb; 41(2):307-10. PubMed ID: 9533479
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
